PASADENA, Calif.–(BUSINESS WIRE)– Arrowhead Research Corporation (NAS: ARWR)
, a targeted therapeutics company, today announced that it recently
filed an application for approval to begin a phase 1 clinical trial of
its RNAi-based therapeutic candidate, ARC-520, against chronic hepatitis
B virus infection. Pending approval, Arrowhead intends to proceed with a
phase 1, randomized, double-blind, placebo-controlled, dose-escalating
study to evaluate the safety, tolerability and pharmacokinetics of
ARC-520 in normal adult volunteers.
The application was submitted to an ethics committee in compliance
with the Clinical Trial Notification process of the Australian
Department of Health and Ageing, Therapeutic Goods Administration.